For people suffering from severe atopic dermatitis (AD), commonly referred to as severe eczema, relief may be in sight, according to a recent article in Dermatology Times. If you’re one of the people with this chronic skin condition who hasn’t found relief using topical corticosteroids and systemic immunosuppressants, more options are on the way.
The article reported that two new therapies have reached clinical practice, and there are a dozen or more topicals and biologics in development for atopic dermatitis.
You may not be able to pronounce the names of these new treatments, but the manufacturers are hopeful that they will provide relief. In the United States, crisaborole (trade name Eucrisa) and dupilumab (trade name Dupixent) have already been approved by the FDA for AD use.
A dozen other biologic agents are under development, including nemolizumab, which could be the first biologic agent designed to control itch. There are oral treatments in the pipeline, too.
There are even more innovations on the way. In 2017, The International Treatment of Atopic Eczema (TREAT) Registry Taskforce was formed to aggregate data collected on systemic immunomodulatory therapies and phototherapy from dermatology communities around the world.
